

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent of:
INVENTOR Masterson, et al.

Patent No.: 5,540,938

Issued: July 30, 1996

For: FORMULATIONS AND THEIR USE IN THE
TREATMENT OF NEUROLOGICAL
DISEASES

Mail Stop: Hatch-Waxman PTE
U.S. Patent and Trademark Office
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

**SUBMISSION REGARDING REQUEST FOR EXTENSION OF
PATENT TERM UNDER 35 U.S.C. §156**

Dear Madam:

This submission is being made pursuant to 21 U.S.C. § 1.765 to highlight certain developments that have occurred regarding U.S. Patent No. 5,540,938 (“the ‘938 patent”) since the filing of the Request for Extension of Patent Term Under 35 U.S.C. § 156 for the ‘938 patent and relating to AMPYRA® (dalfampridine) Extended Release Tablets (“Request”).

First, the ‘938 patent has been assigned from Elan Pharma International Ltd. to EDT Pharma Holdings Limited, by virtue of an assignment recorded on January 13, 2012 at Reel 027528, Frame 0872 (Exhibit 1), and EDT Pharma Holdings Limited has changed its name to


Alkermes Pharma Ireland Limited (“Alkermes”), by virtue of a document recorded on January 13, 2012 at Reel 027528, Frame 0921(Exhibit 2). Also attached is the Patent Assignment Abstract of Title, available at <http://assignments.uspto.gov/assignments>, which reflects these transfers of rights as well as security agreements that have been recorded in favor of Morgan Stanley Senior Funding, Inc. (Exhibit 3). In view of the above, Alkermes represents that it is the current owner and assignee of the entire interest in and to the ‘938 patent, and thus the current Applicant for the previously-filed Request instead of Elan Pharma International Ltd. Accordingly, attached to this submission is a letter from Alkermes authorizing the marketing applicant, Acorda Therapeutics, Inc., to continue to prosecute the patent term extension application on Alkermes’ behalf, as represented by Covington & Burling LLP, pursuant to 37 C.F.R. § 1.730(c) (Exhibit 4).

Second, a Certificate of Correction was issued on May 8, 2012 with respect to the ‘938 patent, a copy of which is attached (Exhibit 5), to correct certain priority information set forth on the face of the ‘938 patent. Further to the Certificate of Correction and updating the statements made in the Request, the ‘938 patent matured from United States Patent Application No. 08/328,165, filed on October 24, 1994 (“the ‘165 application”). The ‘165 application is a divisional of U.S. Patent Application No. 08/073,651, filed on June 7, 1993, now U.S. Patent No. 5,370,879, which is a continuation of U.S. Patent Application No. 07/786,400, filed on November 1, 1991, now abandoned. Moreover, the ‘938 patent also claims foreign priority from Irish Application No. 3952/90, filed on November 2, 1990. This correction does not affect the calculation of the patent term extension to which the ‘938 patent is entitled.

Please direct any inquiries regarding this submission or this application to the undersigned attorneys.

Dated: July 16, 2012

Respectfully submitted,

By 
Natalie M. Derzko

Registration No.: 48,102

Christopher N. Sipes

Registration No.: 39,837

COVINGTON & BURLING LLP

1201 Pennsylvania Avenue, N.W.

Washington, DC 20004-2401

(202) 662-6000

Attorneys for Acorda Therapeutics, Inc.

EXHIBIT 1

**TO SUBMISSION REGARDING REQUEST FOR
EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156**

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Elan Pharma International Limited	08/02/2011
RECEIVING PARTY DATA	
Name:	EDT Pharma Holdings Limited
Street Address:	Treasury Building
Internal Address:	Grand Canal Street Lower
City:	Dublin 2
State/Country:	IRELAND
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	5370879
Patent Number:	5540938
Patent Number:	5580580
CORRESPONDENCE DATA	
Fax Number:	(609)896-1469
Phone:	609-844-3024
Email:	sklosek@foxrothschild.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Sarah Klosek
Address Line 1:	997 Lenox Drive, Bldg. 3
Address Line 2:	Fox Rothschild LLP
Address Line 4:	Lawrenceville, NEW JERSEY 08648
NAME OF SUBMITTER:	Sarah Klosek
Total Attachments: 14 source=Asset_transfer#page1.tif source=Asset_transfer#page2.tif	

OP \$120.00 5370879

source=Asset_transfer#page3.tif
source=Asset_transfer#page4.tif
source=Asset_transfer#page5.tif
source=Asset_transfer#page6.tif
source=Asset_transfer#page7.tif
source=Asset_transfer#page8.tif
source=Asset_transfer#page9.tif
source=Asset_transfer#page10.tif
source=Asset_transfer#page11.tif
source=Asset_transfer#page12.tif
source=Asset_transfer#page13.tif
source=Asset_transfer#page14.tif

Step 6
Trading Assets Agreement (EPIL to EDT Pharma Holdings)

Dated 2 August 2011

ELAN PHARMA INTERNATIONAL LIMITED
(Vendor)

and

EDT PHARMA HOLDINGS LIMITED
(Purchaser)

ASSET TRANSFER AGREEMENT

for the purchase of the trading assets relating to the Drug Delivery Business of
ELAN PHARMA INTERNATIONAL LIMITED

A & L GOODBODY

THIS ASSET TRANSFER AGREEMENT is dated 2 August 2011 and made between

- (1) **ELAN PHARMA INTERNATIONAL LIMITED** (registered no. 222276) having its registered office at Monksland, Athlone, Co. Westmeath (**Vendor**); and
- (2) **EDT PHARMA HOLDINGS LIMITED** a company incorporated in Ireland (Registered No. 448848) whose registered office is at Treasury Building, Grand Canal Street Lower, Dublin 2 (**Purchaser**).

RECITALS:

- A. The Vendor is carrying on a trade of the purchase, development and exploitation of certain intellectual property rights and is the owner of certain trading assets (including intellectual property rights) relating to the EDT Business.
- B. Under the Business Transfer Agreement, the Purchaser has acquired the manufacturing business forming part of the EDT Business including the employees engaged in connection therewith.
- C. The Vendor has agreed to sell and the Purchaser has agreed to purchase the Trading Assets upon the terms and subject to the conditions of this Agreement and will use these trading assets in the course of its manufacturing business.
- D. As set out in Section 7.1(k) of the Merger Agreement, the Purchaser will, for so long as it is a member of the Elan Tax Group, carry on its business in the same manner as the Vendor and will carry the Trading Assets as trading stock for tax purposes. The Trading Assets under this Agreement should not include any assets relating to the EDT Business other than assets which were held as trading stock by the Vendor.

IT IS HEREBY AGREED as follows:

1. PRELIMINARY

- 1.1. Definitions:** In this Agreement and in the Schedules unless the context otherwise requires:

1963 Act means the Companies Act, 1963;

1990 Act means the Companies Act, 1990;

Authorisations means those authorisations, licences and permits necessary for the conduct of the EDT Business which are in the name of the Purchaser;

Business Contracts means all contracts, agreements, arrangements and understandings of every kind with customers of the EDT Business and other contracts relating to the EDT Business, which form part of the Trading Assets;

Business Day means any day on which banks are generally open for business in Dublin excluding Saturdays and Sundays;

Business Transfer Agreement means the agreement dated 26 July 2011 pursuant to which the Purchaser has acquired the Manufacturing Business from Elan Science Five Limited;

Completion means completion of the sale and purchase of the Trading Assets pursuant to this Agreement;

Conditions means the pre-conditions to closing listed in clause 3.2;

Confidential Information means any and all information received or obtained as a result of (i) the operation of the EDT Business and/or (ii) entering into or performing, or supplied by or on behalf of a party in the negotiations leading to, this Agreement and which in each case relates to:

- (a) the EDT Business;

- (b) the Manufacturing Business;
- (c) the provisions of this Agreement;
- (d) the negotiations relating to this Agreement;
- (e) the subject matter of this Agreement; or
- (f) the Purchaser or any subsidiary or holding company of the Purchaser;

EDT Business means the suite of activities including: research, development, drug optimization and delivery utilizing Elan's proprietary drug delivery technologies (including its NanoCrystal® technology for poorly water-soluble compounds, and its range of oral controlled release delivery technologies comprising extended, delayed and pulsatile release); drug scale up capabilities including formulation development, analytical development, clinical trial manufacturing and scale-up and product registration support; performing such research and development services for third parties; licensing or otherwise permitting the practice and use by third parties of such Elan proprietary drug delivery technologies or products incorporating such drug delivery technologies; and commercial manufacturing of pharmaceutical dosage forms both for products incorporating Elan proprietary technologies, the Fill/Finish Business and all contract manufacturing carried on by the Vendor;

Effective Date means the date of this Agreement;

Employees means those employees of the Vendor employed in connection with the Trading Assets;

Elan Tax Group means Elan Corporation plc and all of its wholly owned direct and indirect subsidiaries resident for tax purposes in Ireland;

Encumbrance includes, without limitation, any interest or equity of any person (including any right to acquire any option) or any mortgage, charge, pledge, lien, assignment, hypothecation, security interest (including any created by law), title retention or other security agreement or arrangement or a rental, hire purchase, credit sale or other agreement for payment on deferred terms;

Excluded Assets means those assets of the Vendor set out in Schedule 1 which are not being sold hereunder;

Fill/Finish Business means the fill/finish business carried on by the Vendor at Building 17 on the EDT Business campus at Monkstown Industrial estate, Athlone, Co. Westmeath;

Information means all customer and supplier records and correspondence (including, in each case, the full name and the address and addresses for delivery or collection or for provision of services) relating to the EDT Business, all books of account relating to the EDT Business and other records of the EDT Business for the six years prior to Completion, all deeds and documents evidencing title to the Trading Assets (duly stamped where appropriate), all sales and technical literature and all other documents, computer records and programs relating to or required for the due and efficient carrying on of the EDT Business and all files and other relevant information relating to the Employees;

Intellectual Property means any and all rights pertaining to inventions, discoveries, trade secrets, confidential business information, financial, marketing and business data, concepts, ideas and improvements to existing technology (in each case whether or not written down or otherwise converted to tangible form), patents, patent applications, patent disclosures, designs, trade marks, service marks, trade names, logos, rights in any domain names, algorithms, database rights, goodwill, copyright(s), moral rights, know-how, reputation, modes, get-up, computer programs and analogous property, plans, models, and all other forms of industrial or intellectual property (in each case in any part of the world and whether or not registered or registerable and to the fullest extent thereof and for the full period therefor and all extensions and renewals thereof), all applications for registration of the foregoing and all rights and interest, present and future thereto and therein;

Intellectual Property Rights means such Intellectual Property used exclusively in connection with the EDT Business and such other Intellectual Property as are included in the Trading Assets;

Ireland means Ireland excluding Northern Ireland and Irish will be construed accordingly;

Licence User Agreement means an agreement entered into on today's date by the Vendor and the Purchaser pursuant to which the Vendor agrees to sub-licence the Authorisations to the Purchaser;

Loan Note means the loan note to be issued by the Purchaser in the name of the Vendor in the amount of US\$299,000,000 on Completion pursuant to clause 3.4;

Manufacturing and Supply Agreement means the agreement entered into by Elan Science Five Limited (ES5) and the Vendor on 26 July 2011 whereby ES5 has agreed to manufacture and supply to the Vendor certain products and the Vendor has agreed to purchase the products upon the terms set out in the agreement;

Manufacturing Business means all the capital assets, manufacturing assets, real property, fixtures and fittings and all other assets owned by the Vendor, other than the Excluded Assets including the Vendor's obligations under the Manufacturing and Supply Agreement, which are to be acquired by the Purchaser pursuant to the Business Transfer Agreement;

Merger Agreement means the business combination agreement and plan of merger entered into by Elan Corporation, plc, Antler Science Two Limited, Elan Science Four Limited, EDT Pharma Holdings Limited, EDT US Holdco Inc., Antler Acquisition Corp. and Alkermes, Inc. on 9 May 2011;

Patents means the patents listed at Schedule 2 to this Agreement;

Taxation and Tax means all forms of taxation, duties, imposts and levies whether of Ireland or elsewhere, including (but without limitation) income tax, corporation tax, corporation profits tax, advance corporation tax, capital gains tax, capital acquisitions tax, residential property tax, wealth tax, value added tax, customs and other import and export duties, excise duties, vehicle registration tax, stamp duty, capital duty, social insurance, social welfare or other similar contributions and other amounts corresponding thereto whether payable in Ireland or elsewhere, and any costs, interest, surcharge, penalty or fine relating to the same and any penalties chargeable for non-compliance with any statutory provisions or regulations in connection therewith and the word **taxation** shall be construed accordingly;

TCA means the Taxes Consolidation Act, 1997;

Termination Letter means a letter dated the date of this Agreement between the Vendor and the Purchaser pursuant to which the Manufacturing and Supply Agreement is to be terminated;

Trading Assets means the assets listed in Clause 2.1 including all the Intellectual Property owned by the Vendor in respect of or related to the EDT Business, other than for the avoidance of doubt the Excluded Assets, all of which are to be acquired by or novated in favour of the Purchaser pursuant to this Agreement; and

VAT means value added tax within the meaning of the Value-Added Tax Consolidation Act 2010.

- 1.2. The Schedules referred to in this Agreement form an integral part of this Agreement, and references to this Agreement include reference to them.
- 1.3. Headings are inserted for convenience only and do not affect the construction of this Agreement.
- 1.4. All references in this Agreement to costs, charges or expenses include any value added tax or similar tax charged or chargeable on them.
- 1.5. Unless expressly stated in this Agreement or the context otherwise requires, in this Agreement:
 - 1.5.1. references to persons are deemed to include references to natural persons, firms, partnerships, companies, corporations, associations, bodies corporate, trusts and investment funds (in each case whether or not having a separate legal personality) but references to individuals are deemed to be references to natural persons only;
 - 1.5.2. words importing the singular include the plural and vice versa and words importing the masculine include references to the feminine and neuter and vice versa;
 - 1.5.3. reference to writing or similar expressions includes transmission by facsimile or electronic means;

- 1.5.4. a word or phrase the definition of which is contained or referred to in section 2 of the 1963 Act has the meaning attributed to it by that definition;
- 1.5.5. references to Acts, statutory instruments and other legislation are to legislation operative in Ireland and to such legislation, modified, consolidated, amended or re-enacted (whether before or after the date of this Agreement) and any subordinate legislation made under that legislation;
- 1.5.6. reference to any Irish legal term, concept, legislation or regulation (including, those for any action, remedy, method of judicial proceeding, document, statute, court official, governmental authority or agency) or any accounting term or concept, in respect of any jurisdiction other than Ireland will be construed as a reference to the term or concept which most nearly corresponds to it in that jurisdiction;
- 1.5.7. reference to this Agreement includes this Agreement as amended or supplemented from time to time; and
- 1.5.8. "including" and "includes" mean including or includes without limiting the generality of the foregoing.

2. SALE OF ASSETS

- 2.1. **Sale and Purchase:** Subject to the terms of this Agreement, the Vendor shall sell as legal and beneficial owner and the Purchaser shall purchase in reliance on the provisions of this Agreement free from all Encumbrances and together with all rights now or hereafter attaching thereto, the Trading Assets including:

- 2.1.1. the Patents;
- 2.1.2. the Intellectual Property Rights
- 2.1.3. subject to clause 4 the full benefit subject to the burden (so far as the same is capable of assignment) of the Business Contracts and all of the Vendor's pending contracts engagements and all orders in connection with the EDT Business;
- 2.1.4. the Authorisations;
- 2.1.5. any related goodwill of the EDT Business and to represent the Purchaser as carrying on the EDT Business in continuation of that carried on by the Vendor and in succession thereto;
- 2.1.6. the Information; and
- 2.1.7. all other property in connection with the Intellectual Property Rights except the Excluded Assets.

- 2.2. **Other Benefits:**

- 2.2.1. If the Vendor receives any sums or benefits in respect of any of the Trading Assets it shall forthwith pay or cause to be paid (as the case may be) to the Purchaser as soon as practicable and in any event within ten Business Days of receipt thereof to a bank account to be nominated by the Purchaser it being recognised and agreed by the Vendor that, if the Purchaser so requires, the Purchaser shall continue to invoice any customers in respect of contracts current at Completion.
- 2.2.2. The Vendor shall forthwith upon the execution hereof notify the interest of the Purchaser to the insurers of the Trading Assets and the EDT Business and keep in force its existing insurance policies in respect of the Trading Assets until 180 days after Completion.

- 2.3. **The Consideration:**

The consideration for the said sale shall be satisfied by the issue of the Loan Note in the name of the Vendor.

- 2.4. **Purchase of all the Trading Assets:** The Purchaser will not be obliged to complete the purchase of

any of the Trading Assets unless the purchase of all of the Trading Assets is completed simultaneously.

2.5. Value Added Tax (VAT):

- 2.5.1. The parties shall use their best endeavours to ensure that by virtue of the provisions of sections 20(2)(c) and 26(2) of the Value-Added Tax Consolidation Act 2010 no VAT will be chargeable in respect of the sale and purchase of the Trading Assets hereby agreed to be made.
- 2.5.2. Notwithstanding Clause 2.5.1, the Purchaser shall not be liable to pay to the Vendor or to any other person any amount representing VAT in respect of the sale of the Trading Assets unless the Vendor demonstrates to the satisfaction of the Purchaser that the provisions of sections 20(2)(c) and 26(2) of the Value-Added Tax Consolidation Act 2010 do not apply. For the avoidance of doubt, written confirmation from the Irish Revenue Commissioners on this point shall be treated as demonstration to the satisfaction of the Purchaser.
- 2.5.3. Subject to Clause 2.5.2, if VAT is properly chargeable in respect of the sale of the Trading Assets and the Vendor is accountable in respect of the payment of the VAT to the VAT authorities, the Vendor shall deliver to the Purchaser a VAT invoice prepared in a format which is in accordance with relevant VAT legislation. On receipt of this VAT invoice the Purchaser shall pay to the Vendor the amount of VAT properly arising in respect of the sale of the Trading Assets.
- 2.5.4. Notwithstanding Clause 2.5.2, if following the payment of any amount of VAT by the Purchaser to the Vendor in respect of the sale of the Trading Assets it is established that VAT was incorrectly chargeable, the Vendor shall pay to the Purchaser the amount of any VAT incorrectly charged. For the avoidance of doubt, only written confirmation from the Irish Revenue Commissioners shall be treated as establishing that VAT was incorrectly chargeable.
- 2.5.5. In the event that the Vendor will incur a clawback of VAT in relation to or arising from the sale, the parties hereby exercise a joint option to tax within the meaning of section 94(5) Value-Added Tax Consolidation Act 2010.

3. COMPLETION AND CONDITIONS

- 3.1. **Completion:** Subject to clause 3.2, Completion shall take place on the Effective Date at such address as the parties may agree.
- 3.2. **Closing Conditions:** Completion of this Agreement will take place conditionally upon:
 - 3.2.1. the simultaneous completion of the Business Transfer Agreement; and
 - 3.2.2. the Vendor having complied with its obligations under clause 5.
- 3.3. **Actions at Completion:** Upon Completion:
 - 3.3.1. possession of the Trading Assets shall, as far as practical, be delivered to the Purchaser;
 - 3.3.2. the Vendor shall procure that all other necessary parties (if any) execute and deliver to the Purchaser all such assurances and things as may be necessary to vest in the Purchaser good and marketable title to the Trading Assets (including deeds of assignment in relation to the Intellectual Property) including such evidence of corporate power and proper execution as the Purchaser may reasonably require;
 - 3.3.3. the Vendor and the Purchaser shall execute and deliver the Termination Letter;
 - 3.3.4. the Vendor and the Purchaser shall execute and deliver the Licence User Agreement;
 - 3.3.5. the Vendor and the Purchaser shall comply with the terms of clause 5 (in relation to the Employees); and
 - 3.3.6. the Vendor shall cause to be delivered to the Purchaser a tax clearance certificate pursuant to section 980 of the Taxes Consolidation Act 1997 (as amended) (**CGT Clearance Certificate**)

confirming that the Purchaser does not have to deduct any sum representing capital gains tax on payment of the consideration to the Vendor.

- 3.4. **Payments at Completion:** The Purchaser shall on Completion issue the Loan Note in the name of the Vendor less withholding tax if the CGT Clearance Certificate is not produced by the Vendor stating that tax should not be deducted from the consideration.

4. BUSINESS CONTRACTS

- 4.1. At Completion the Vendor will, at the option of the Purchaser, in respect of each Business Contract:-

4.1.1. assign (or procure the assignment of) the Business Contract in question to the Purchaser or its nominee(s); or

4.1.2. procure the novation of the Business Contract in question so that the Purchaser or its nominee(s) will become party to the relevant Business Contract in place of the Vendor

in each case on such terms as may be agreed to by the Purchaser.

- 4.2. Insofar as the consent of a third party is required to comply with the terms of clause 4.1, the Vendor shall use its best endeavours to procure such consent at its own cost and expense. Until such consent is received, the Vendor shall, following Completion, at the Purchaser's option either:-

4.2.1. unless contractually prevented from so doing, sub-contract the relevant Business Contract to the Purchaser on the same terms and for the same remuneration that applies to that Business Contract; or

4.2.2. act in connection with the Business Contract in all respects as the Purchaser may reasonably direct from time to time

so that (without prejudice to generality of the foregoing) the Purchaser will perform the obligations and liabilities arising under the Business Contract in question insofar as any such obligation or liability arises after Completion (provided that no such obligation or liability is in respect of any breach of the relevant Business Contract by the Vendor prior to Completion) and the full benefit of all contractual rights, benefits and claims thereunder whether arising before or after Completion shall vest in and be held on trust by the Vendor for the Purchaser absolutely.

- 4.3. To the extent that the Vendor is not lawfully able to hold the Business Contract in question on trust for the Purchaser, the parties shall make such other arrangements between themselves as the Purchaser may reasonably require to provide that (i) the benefit of the Business Contracts in question is received by the Purchaser, including the enforcement of all rights of the Vendor thereunder and (ii) the Purchaser will be responsible for carrying out the Vendor's obligations under such Business Contracts as set out above from Completion.

- 4.4. If any Business Contract is being novated then this Agreement does not act as a contract or agreement for the sale of any estate or interest in the Business Contracts nor does it operate to assign any of the Business Contracts. Instead the benefit of the Business Contracts will be novated to the Purchaser pursuant to the deed of novation which is to be entered into between the parties.

5. EMPLOYEES

- 5.1. **Safeguarding of Employees' Rights:** The Vendor shall discharge all of its obligations (if any) in relation to the Employees arising under or by virtue of the European Communities (Protection of Employees on Transfer of Undertakings) Regulations, 2003.

- 5.2. **Evidence and Information:** The Vendor shall both before and after Completion furnish to the Purchaser such evidence and information as the Purchaser may from time to time require in relation to the discharge by the Vendor of the Vendor's said obligations together with such other information as the Purchaser may from time to time require in relation to the intentions, proposals, obligations and actions of the Vendor in connection with contracts of employment, employment relationships or collective agreements and any other matters in connection therewith relating to any of the Employees.

- 5.3. **Other Obligations:** The Vendor shall perform and shall be fully liable and responsible for all obligations

and liabilities whatsoever pertaining to matters arising prior to Completion arising by virtue of or in connection with contracts of employment, employment relationships and/or collective agreements in existence at any time prior to Completion (whether discovered before or after Completion) including under any applicable statute and the Vendor hereby fully and effectually indemnifies and agrees to keep the Purchaser fully and effectually indemnified against all judgments, claims, decrees, prosecutions, orders, awards, damages, costs, liabilities and expenses howsoever arising (including costs, payments and expenses of any reasonable settlement entered into by the Purchaser with the prior consent of the Vendor, such consent not to be unreasonably withheld, delayed or conditioned) under or by virtue thereof. In the event that any claim, arising from circumstances prior to Completion, is made against the Purchaser, the Vendor shall furnish to the Purchaser such evidence and information as the Purchaser may require to defend those claims.

- 5.4. **Transfer of Employees:** The Vendor shall prior to Completion comply where appropriate with sections 9(2) and 20 of the Redundancy Payments Act, 1967 and shall facilitate the Purchaser in this regard so that continuity, where appropriate, is maintained.
- 5.5. The Vendor and the Purchaser shall not prior to the Effective Time unless otherwise required by law or with the prior agreement of Alkermes, Inc.
- 5.5.1. increase or offer, promise or agree to increase the remuneration (howsoever defined but including salary and any variable and/or incentive arrangements) or the severance arrangements in respect of any of the Employees;
- 5.5.2. increase or make offers of employment so as to increase the number of the Employees; or
- 5.5.3. replace or offer to redeploy any of the Employees.

6. MISCELLANEOUS PROVISIONS

6.1. Confidentiality

6.1.1. The Vendor undertakes with the Purchaser that it shall preserve the confidentiality of, and not directly or indirectly reveal, report, publish, disclose, transfer or use for its own or any other purposes Confidential Information except:

- (1) in the circumstances set out in clause 6.1.2;
- (2) to the extent otherwise expressly permitted by this Agreement; or
- (3) with the prior written consent of the Purchaser.

6.1.2. The Vendor is permitted to disclose Confidential Information:

- (1) where the Confidential Information, before it is furnished to the relevant Vendor, is in the public domain;
- (2) where the Confidential Information, after it is furnished to the relevant Vendor, enters the public domain otherwise than as a result of: (i) a breach by the relevant Vendor of its obligations in this clause 6.1 or (ii) a breach by the person who disclosed that Confidential Information of a confidentiality obligation where the relevant Vendor is aware of such breach;
- (3) If and to the extent that a Vendor discloses Confidential Information to any person:
 - (a) in compliance with any requirement of law;
 - (b) in response to a requirement of any securities exchange, regulatory or governmental authority or court having jurisdiction over the relevant Vendor; or
 - (c) in order to obtain Tax or other clearances or consents from the Revenue Commissioners or other relevant taxing or regulatory authorities,

provided that any such information disclosable pursuant to paragraphs (a), (b) or (c) may be disclosed only to the extent specifically required by law.

6.1.3. The restrictions contained in this clause 6.1 will continue to apply after Completion and will apply in relation to the existence and provisions of this Agreement and Information relating to the Purchaser regardless of whether or not Completion occurs.

6.2. Severability

All the terms and provisions of this Agreement are distinct and severable, and if any term or provision is held or declared to be unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it will to that extent only be deemed not to form part of this Agreement, and the enforceability, legality and validity of the remainder of this Agreement will not in any event be affected. The parties shall then use all reasonable endeavours to agree a term or provision to replace the unenforceable, illegal or void term or provision which is legal and enforceable and which has an effect that is near as possible to the intended effect of the term or provision to be replaced.

6.3. Whole Agreement

This Agreement (together with any documents to be executed pursuant to the terms of this Agreement) supersedes all prior representations, arrangements, understandings and agreements, and sets out the entire, complete and exclusive agreement and understanding between the parties. The rights of the Purchaser under this Agreement are independent, cumulative and without prejudice to all other rights available to it whether as a matter of common law, statute, custom or otherwise.

6.4. Survival

The provisions of this Agreement which have not been performed at Completion will remain in full force and effect notwithstanding Completion.

6.5. Remedies Cumulative

The provisions of this Agreement and the rights and remedies of the parties are cumulative and are without prejudice and in addition to any rights or remedies which a party may have at law or in equity. The exercise by a party of any one right or remedy under this Agreement or at law or in equity will not (unless expressly otherwise provided in this Agreement or at law or in equity) operate so as to hinder or prevent the exercise by that party of any other right or remedy.

6.6. Waiver

Any liability to the Purchaser under this Agreement may be wholly or partially released, varied, compounded or compromised by the Purchaser in its absolute discretion as regards the Vendor or any other party without in any way prejudicing or affecting its rights against any other party under the same or a similar liability, whether joint and several or otherwise. A waiver by the Purchaser of any breach by any party of any of the terms, provisions or conditions of this Agreement, or the acquiescence of the Purchaser in any act (whether commission or omission) which but for such acquiescence would be a breach, will not constitute a general waiver of the term, provision or condition or of any subsequent act which is inconsistent with it.

6.7. Further Assurance

6.7.1. Without limiting the generality of the foregoing, to the extent that the Purchaser or the Vendor discover following Completion that:

6.7.2. any Trading Asset that was intended to be assigned and transferred pursuant to this Agreement was not assigned and transferred at Completion, the Vendor shall (and shall procure that any other necessary parties shall) execute and do all such documents, acts and things as may reasonably be required to assign and transfer to the Purchaser the legal and beneficial ownership in such Trading Asset; and/or

6.7.3. any asset that was not a Trading Asset intended to be transferred pursuant to this Agreement was assigned and transferred at Completion, the Purchaser shall (and shall procure that any other parties shall) execute and do all such documents, acts and things as may reasonably be

required to assign and transfer to the Vendor the legal and beneficial ownership in such asset.

6.8. Notices

Any notice or other communication to be given or served under this Agreement shall be in writing, addressed to the relevant party and expressed to be a notice or communication under this Agreement and, without prejudice to the validity of another method of service, may be delivered or sent by pre-paid post or facsimile addressed to the recipient at the address given above or to its fax number at that address.

6.9. Counterparts

This Agreement may be executed in any number of counterparts, and by the several parties to it on separate counterparts, each of which when so executed will constitute an original but all of which together will evidence the same agreement.

6.10. Governing Law and Jurisdiction

This Agreement and all relationships created by it will in all respects be governed by and construed in accordance with Irish law. The Irish courts will have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement or its performance.

6.11. Succession and Assignment

This Agreement will be binding upon and enure for the benefit of the permitted assigns and, where applicable, successors in title, administrators, executors and personal representatives of the parties. The benefit of any provision of this Agreement may be enforced by the beneficial owners for the time being of the EDT Business or any of the Trading Assets, and accordingly the benefit of any provision in this Agreement may be assigned at any time and from time to time by the Purchaser and its successors in title without the consent of the Vendor.

6.12. Variations

This Agreement may not be released, varied, discharged, amended or supplemented, except by an instrument in writing executed by each party or a duly authorised representative of each party.

6.13. Financial Transfers


The Vendor declares for the purpose of the Financial Transfers Act, 1992 that it is not resident in any jurisdiction to which financial transfers (within the meaning of that Act) are restricted by order of the Minister for Finance in accordance with the provisions of that Act and does not hold any of the Trading Assets, and will not receive any part of the consideration, as nominee for any persons so resident, and the Purchaser declares for the purpose of that Act that it is not so resident, is not acquiring the Trading Assets as nominee for any persons so resident and that the Purchaser is not to its knowledge controlled directly or indirectly by persons so resident.

6.13.1. Recitals


The parties acknowledge that matters referred to in the recitals will not, in any way, give rise to any liability or cause of action against the Purchaser.

IN WITNESS whereof this Agreement has been entered into on the date and year first herein written.

SIGNED for and on behalf of
ELAN PHARMA INTERNATIONAL LIMITED


Director

SIGNED for and on behalf of
EDT PHARMA HOLDINGS LIMITED


Director

SCHEDULE 1

Excluded Assets

For the avoidance of doubt, the Excluded Assets of the Vendor means:

- (1) all those assets and records of the Vendor which do not form part of the EDT Business
- (2) all cash and bank accounts of the Vendor;
- (3) the Manufacturing Business; and
- (4) the statutory books of the Vendor.

SCHEDULE 2

Patents

PATENT

REEL: 027528 FRAME: 0886

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	SAC Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
02.1008.US	2 ORD	USA		11/323,893	US 2006-0269596 A1	11-Jan-2006	11-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ACYLANILIDE
02.1011.US	2 ORD	USA		11/568,841		29-Jun-2007	14-Feb-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING LEVETIRACETAM
02.1012.US	2 ORD	USA		11/571,379		12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
02.1013.US	2 ORD	USA		11/558,202	US 2007-0122481 A1	09-Nov-2006	01-Nov-2019	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
02.1103.US	CIP	USA		11/568,925		16-Nov-2006	01-Nov-2019	MODIFIED RELEASE COMPOSITIONS COMPRISING A MODIFIED RELEASE OF COMPOSITIONS CONTAINING A COMBINATION OF CARBIDOPA, LEVODOPA AND ENTACAPONE
02.1107.US	2 PCT	USA		11/422,226	US 2008-0118556 A1	05-Jun-2006	01-Nov-2019	CONTROLLED RELEASE PHARMACEUTICAL FORMULATION
02.1200.US	4 CON	USA	5505962	08/307,392		16-Sep-1994	09-Apr-2013	CONTROLLED RELEASE BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING CYCLOSPORIN
02.1255.US	ORD	USA	5641745	08/479,509		07-Jun-1995	07-Jun-2015	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
02.1301.US	4 CON	USA	5364620	07/921,459		28-Jul-1992	15-Nov-2011	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
02.1301.US	5 DIV	USA	5616345	08/334,864		04-Nov-1994	01-Apr-2014	DILTIAZEM FORMULATION AND METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
02.1303.US	3 CON	USA	5336504	08/064,401		19-May-1993	22-Jul-2012	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1806.US	2 CON	USA	5370879	08/073,651		07-Jun-1993	08-Dec-2011	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1806.US	3 DIV	USA	5540938	05/328,185		24-Oct-1994	30-Jul-2013	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1806.US	4 DIV	USA	5580580	08/478,506		07-Jun-1995	03-Dec-2013	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1807.US	ORD	USA	5533995	08/244,094		13-May-1994	09-Jul-2013	PASSIVE TRANSDERMAL DEVICE WITH CONTROLLED DRUG DELIVERY
02.1809.US	2 ORD	USA	6066329	08/977,985		25-Nov-1997	25-Nov-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
02.1816E.US	2 CON	USA	6228398	09/586,636		06-May-2000	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	3 CON	USA	6730325	09/850,425	US 2002-0054907 A1	07-May-2001	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	4 CON	USA	6802742	10/331,754	US 2003-0129237 A1	30-Dec-2002	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	5 CON	USA	6793936	10/354,483	US 2003-0170304 A1	30-Jan-2003	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	6 CON	USA		10/627,689	US 2004-0197405 A1	19-Apr-2004	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	7 CIP	USA		11/372,857	US 2006-0240106 A1	10-Mar-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)

EXHIBIT 2

**TO SUBMISSION REGARDING REQUEST FOR
EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156**

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
EDT Pharma Holdings Limited	09/14/2011
RECEIVING PARTY DATA	
Name:	Alkermes Pharma Ireland Limited
Street Address:	Treasury Building
Internal Address:	Grand Canal Street Lower
City:	Dublin 2
State/Country:	IRELAND
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	5370879
Patent Number:	5540938
Patent Number:	5580580
CORRESPONDENCE DATA	
Fax Number:	(609)896-1469
Phone:	609-844-3024
Email:	sklosek@foxrothschild.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Sarah Klosek
Address Line 1:	997 Lenox Drive, Bldg. 3
Address Line 2:	Fox Rothschild LLP
Address Line 4:	Lawrenceville, NEW JERSEY 08648
NAME OF SUBMITTER:	Sarah Klosek
Total Attachments: 2 source=certificateofincorporation#page1.tif source=certificateofincorporation#page2.tif	

OP \$120.00 5370879

PATENT

EXHIBIT A

Number 448848

Certificate of Incorporation on change of name

I hereby certify that

EDT PHARMA HOLDINGS LIMITED


having, by a Special Resolution of the Company,
and with the approval of the Registrar of Companies,
changed its name, is now incorporated
as a limited company under the name

ALKERMES PHARMA IRELAND LIMITED

and I have entered such name on the Register accordingly.

Given under my hand at Dublin, this

Wednesday, the 14th day of September, 2011



for Registrar of Companies

PATENT

RECORDED: 01/13/2012

REEL 027528 FRAME 0923

EXHIBIT 3

**TO SUBMISSION REGARDING REQUEST FOR
EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156**



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)Assignments on the Web > [Patent Query](#)**Patent Assignment Abstract of Title**

**NOTE: Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.**

Total Assignments: 5**Patent #:** 5540928**Issue Dt:** 07/30/1996**Application #:** 08328165**Filing Dt:** 10/24/1994**Inventors:** JOSEPH G. MASTERSON, MICHAEL MYERS**Title:** FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES**Assignment: 1****Reel/Frame:** 021266/0957**Recorded:** 07/23/2008**Pages:** 14**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignor:** ELAN CORPORATION PLC**Exec Dt:** 12/31/2006**Assignee:** ELAN PHARMA INTERNATIONAL LIMITED

MONKSLAND

ATHLONE CO.

WESTMEATH, IRELAND

Correspondent: LINDETTE C. THORNTON

2000 MARKET STREET

TENTH FLOOR

PHILADELPHIA, PA 19103

Assignment: 2**Reel/Frame:** 027528/0872**Recorded:** 01/13/2012**Pages:** 16**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignor:** ELAN PHARMA INTERNATIONAL LIMITED**Exec Dt:** 08/02/2011**Assignee:** EDI PHARMA HOLDINGS LIMITED

TREASURY BUILDING

GRAND CANAL STREET LOWER

DUBLIN 2, IRELAND

Correspondent: SARAH KLOSEK

997 LENOX DRIVE, BLDG. 3

FOX ROTHSCHILD LLP

LAWRENCEVILLE, NJ 08648

Assignment: 3**Reel/Frame:** 027528/0921**Recorded:** 01/13/2012**Pages:** 3**Conveyance:** CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).**Assignor:** EDI PHARMA HOLDINGS LIMITED**Exec Dt:** 09/14/2011**Assignee:** ALKERMES PHARMA IRELAND LIMITED

TREASURY BUILDING

GRAND CANAL STREET LOWER

DUBLIN 2, IRELAND

Correspondent: SARAH KLOSEK

997 LENOX DRIVE, BLDG. 3

FOX ROTHSCHILD LLP

LAWRENCEVILLE, NJ 08648

Assignment: 4**Reel/Frame:** 026994/0186**Recorded:** 09/29/2011**Pages:** 51

Conveyance: PATENT SECURITY AGREEMENT (FIRST LIEN)

Assignors: ALKERMES, INC.

Exec Dt: 09/16/2011

ALKERMES PHARMA IRELAND LIMITED

Exec Dt: 09/16/2011

ALKERMES CONTROLLED THERAPEUTICS INC.

Exec Dt: 09/16/2011

Assignee: MORGAN STANLEY SENIOR FUNDING, INC.

1585 BROADWAY

NEW YORK, NEW YORK 10036

Correspondent: ZHENG BAO

3000 EL CAMINO REAL, 6TH FLOOR

SHEARMAN & STERLING LLP

PALO ALTO, CA 94306

Assignment: 5

Reel/Frame: 026994/0245

Recorded: 09/29/2011

Pages: 51

Conveyance: PATENT SECURITY AGREEMENT (SECOND LIEN)

Assignors: ALKERMES, INC.

Exec Dt: 09/16/2011

ALKERMES PHARMA IRELAND LIMITED

Exec Dt: 09/16/2011

ALKERMES CONTROLLED THERAPEUTICS INC.

Exec Dt: 09/16/2011

Assignee: MORGAN STANLEY SENIOR FUNDING, INC.

1585 BROADWAY

NEW YORK, NEW YORK 10036

Correspondent: ZHENG BAO

3000 EL CAMINO REAL, 6TH FLOOR

SHEARMAN & STERLING LLP

PALO ALTO, CA 94306

Search Results as of: 07/13/2012 02:40 PM

If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.3.1

Web interface last modified: Jan 26, 2012 v.2.3.1

[| .HOME | INDEX | SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT](#)

EXHIBIT 4

**TO SUBMISSION REGARDING REQUEST FOR
EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156**

21 March, 2012

Ms. Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
USA

Re: Patent Term Extension Application for U.S. Patent No. 5,540,938

Dear Ms. Till,

This is to advise you that, as an authorized representative of Alkermes Pharma Ireland Limited ("Alkermes"), owner of U.S. Patent No. 5,540,938 ("the '938 patent"), I hereby authorize Acorda Therapeutics, Inc. of 15 Skyline Drive, Hawthorne, New York, ("Acorda") to prosecute the patent term extension application filed under 35 U.S.C. § 156 for the '938 patent ("the Application") on behalf of Alkermes, pursuant to 37 CFR § 1.730(c).

I understand that counsel for Acorda, Covington & Burling LLP, 1201 Pennsylvania Ave. N.W., Washington, D.C., 20004-2401 (C&B), will prosecute the Application as Acorda's representative, pursuant to 37 C.F.R. § 1.730(c), and hereby grant C&B any authorizations from Alkermes necessary for C&B to act in this capacity until further notice.

Sincerely,



Richie Paul, Ph.D.

Director
Alkermes Pharma Ireland Limited

EXHIBIT 5

**TO SUBMISSION REGARDING REQUEST FOR
EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156**

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,540,938
APPLICATION NO. : 08/328165
DATED : July 30, 1996
INVENTOR(S) : Joseph G. Masterson and Michael Myers

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page, in the Related U.S. Application Data section (item [62]), cancel the text reading
“Division of Ser. No. 786,400, Nov. 1, 1991, abandoned, and a division of Ser. No. 73,651, Jun. 7,
1993, Pat. No. 5,370,879” and insert the following text:

--Division of Ser. No. 73,651, Jun. 7, 1993, Pat. No. 5,370,879, which is a continuation of Ser. No.
786,400, Nov. 1, 1991, abandoned.--

Title Page, after the Related U.S. Application Data section (item [62]), a new section should
be added as follows:


--[30] Foreign Application Priority Data

Nov. 2, 1990 [IE] Ireland 3952/90--

Column 1, line 5, cancel the text beginning with “This is a divisional” to and ending “U.S. Pat. No.
5,370,879.” in column 1, line 7, and insert the following text:

--This is a divisional of Ser. No. 08/073,651, filed Jun. 7, 1993, now U.S. Pat. No. 5,370,879, which is
a continuation of Ser. No. 07/786,400, filed Nov. 1, 1991, now abandoned.--

Signed and Sealed this
Eighth Day of May, 2012

A handwritten signature in dark ink, reading "David J. Kappos". The signature is written in a cursive, flowing style with a large initial "D".

David J. Kappos
Director of the United States Patent and Trademark Office